Bladé J, López-Guillermo A, Bosch F, Cervantes F, Reverter J C, Montserrat E, Rozman C
Postgraduate School of Haematology Farreras Valenti, Hospital Clínic i Provincial, University of Barcelona, Spain.
Br J Haematol. 1994 Sep;88(1):117-21. doi: 10.1111/j.1365-2141.1994.tb04986.x.
Two hundred and forty-three patients diagnosed with multiple myeloma (MM) in a single institution over a 22-year period and treated with standard chemotherapy were analysed in an attempt to determine the impact of response to therapy on survival. The overall response rate in 229 evaluable patients was 50.1% (34.9% objective response plus 15.2% partial response). Median survivals of patients with objective and partial response were 43.4 and 42.8 months, respectively, versus 19 months for nonresponders. Median survival of 14 patients who achieved a complete remission was 42 months, whereas in 21 rapid responders (< or = 2 months) median survival was 43.3 months. A significant correlation between response and survival was observed with the landmark (P = 0.0169), the Mantel & Byar (P = 0.0001) and the Cox regression model (P < 0.0001) methods. These results indicate that, in responding patients, neither the degree of response nor the response kinetics has a significant influence on survival. However, the response to therapy is associated with a significantly longer survival in MM patients.
在22年期间，对某一机构中243例诊断为多发性骨髓瘤（MM）并接受标准化疗的患者进行了分析，以确定治疗反应对生存的影响。229例可评估患者的总体缓解率为50.1%（客观缓解率34.9%加上部分缓解率15.2%）。客观缓解和部分缓解患者的中位生存期分别为43.4个月和42.8个月，而无反应者为19个月。14例完全缓解患者的中位生存期为42个月，而21例快速反应者（≤2个月）的中位生存期为43.3个月。采用地标法（P = 0.0169）、Mantel & Byar法（P = 0.0001）和Cox回归模型（P < 0.0001）方法观察到缓解与生存之间存在显著相关性。这些结果表明，在有反应的患者中，反应程度和反应动力学对生存均无显著影响。然而，治疗反应与MM患者显著更长的生存期相关。
